Primary Job Title Founder Primary Organization
Hormones & Me
Location Austin, Texas, United States Regions Southern US Gender Male
Andy Ruiz is the Chief Operations Officer and Partner at Stonegate Pharmacies, Stonegate Pharmacy, Stonegate Pharmacy at the Village and Stonegate Pharmacy at Westlake. He is also an Adjunct Assistant Professor for the University of Texas at Austin College of Pharmacy, faculty preceptor for Midwestern University College of Pharmacy, and faculty
preceptor for Incarnate Word University Feik School of Pharmacy. Andy is also a Fellow of the American College of Apothecaries. He currently serves on the Board of The IACP and IACP Foundation and serves as the Foundation’s Research Committee Chair. Andy attended The University of Texas at Austin for 2 years prior to entering the UTAustin College of Pharmacy where he earned his Doctor of Pharmacy in 2008. After completion of his Doctor of Pharmacy, Andy helped design and implement the first combined Master of Science in Pharmacy and Community Pharmacy Residency. He was also the first trainee of this ASHP accredited residency. After completion of the combined Master of Science/Residency Program, Andy joined an independent pharmacy in San Antonio Texas where he was the Wellness Director and Pharmacist inCharge of their closed door specialty and home infusion pharmacy. In May of 2011, Andy moved to Austin, Texas and joined Texas Compounding Pharmacy. In January of 2012, Andy moved to Stonegate Pharmacy and assumed his current position as business partner and Pharmacist-in-Charge. Andy is responsible for developing Stonegate Pharmacy’s compounding and wellness services.
Andy is currently a member of the National Community Pharmacist Association (NCPA), Texas Pharmacy Association (TPA), American College of Apothecaries (ACA), Alliance of Independent Pharmacists of Texas (AIP), and The International Academy of Compounding Pharmacists (IACP). Andy is also active in research and his current research is focused on the safety and efficacy of various routes of administration for Bioidentical Hormone Replacement Therapy in menopausal women. He hopes to start a new study on the effectiveness of compounded testosterone therapy for men.



